(a) General. Any actuarial memorandum required by the provisions of this subchapter must be prepared in accordance with and subject to the provisions and qualifications of paragraphs (1) - (5) of this subsection.
  (1) In accordance with Insurance Code Chapter 425, Subchapter B, concerning Standard Valuation Law, the appointed actuary must prepare a memorandum to the company describing the analysis done in support of the appointed actuary's opinion regarding the reserves under the opinion. The memorandum must be made available for examination by the commissioner upon the commissioner's request.
  (2) In preparing the memorandum, the appointed actuary may rely on, and include as a part of the appointed actuary's own memorandum, memoranda prepared and signed by other actuaries who are qualified within the meaning of §4.2804 of this title (relating to Definitions), with respect to the areas covered in such memoranda, and so state in the other actuaries' memoranda.
  (3) If the commissioner requests a memorandum and no such memorandum exists or if the commissioner finds that the analysis described in the memorandum fails to meet the standards of the Actuarial Standards Board as required by §4.2805 of this title (relating to General Requirements), or the standards and requirements of this subchapter, the commissioner may designate a qualified actuary to review the opinion and prepare such supporting memorandum as is required for review. The reasonable and necessary expense of the independent review must be paid by the company but will be directed and controlled by the commissioner.
  (4) The reviewing actuary will have the same status as an examiner for purposes of obtaining data from the company, and the work papers and documentation of the reviewing actuary will be retained by the commissioner. The reviewing actuary may not be an employee of a consulting firm involved with the preparation of any prior memorandum or opinion for the insurer required by this subchapter for any one of the current year or the preceding three years.
  (5) In accordance with Insurance Code Chapter 425, Subchapter B, the appointed actuary must prepare a regulatory asset adequacy issues summary, the contents of which are specified in subsection (c) of this section. Texas domestic companies must submit the regulatory asset adequacy issues summary by email to ActuarialDivision@tdi.texas.gov or by paper copy to the Financial Regulation Division, MC: FRD, Texas Department of Insurance, P.O. Box 12030, Austin, Texas 78711-2030 no later than March 15 of the year following the year for which a statement of actuarial opinion based on asset adequacy is required. Nondomestic companies must submit the regulatory asset adequacy issues summary when requested by the commissioner.
(b) Details of the memorandum section documenting asset adequacy analysis. When an actuarial opinion under §4.2806 of this title (relating to Statement of Actuarial Opinion Based on an Asset Adequacy Analysis) is provided, the memorandum must demonstrate that the analysis has been done in accordance with the standards for asset adequacy referred to in §4.2805(c) of this title and any additional standards under this subchapter. The documentation of the assumptions used in paragraphs (1) and (2) of this subsection must be such that an actuary reviewing the actuarial memorandum could form a conclusion as to the reasonableness of the assumptions. The memorandum must specify:
  (1) for reserves:
    (A) product descriptions including market description, underwriting and other aspects of a risk profile and the specific risks the appointed actuary deems significant;
    (B) source of liability in force;
    (C) reserve method and basis;
    (D) investment reserves;
    (E) reinsurance arrangements;
    (F) identification of any explicit or implied guarantees made by the general account in support of benefits provided through a separate account or under a separate account policy or contract and the methods used by the appointed actuary to provide for the guarantees in the asset adequacy analysis;
    (G) documentation of assumptions to test reserves for the following:
      (i) lapse rates (both base and excess);
      (ii) interest crediting rate strategy;
      (iii) mortality;
      (iv) policyholder dividend strategy;
      (v) competitor or market interest rate;
      (vi) annuitization rates;
      (vii) commissions and expenses; and
      (viii) morbidity.
  (2) For assets:
    (A) portfolio descriptions, including a risk profile disclosing the quality, distribution, and types of assets;
    (B) investment and disinvestment assumptions;
    (C) source of asset data;
    (D) asset valuation bases; and
    (E) documentation of assumptions made for:
      (i) default costs;
      (ii) bond call function;
      (iii) mortgage prepayment function;
      (iv) determining market value for assets sold due to disinvestment strategy; and
      (v) determining yield on assets acquired through the investment strategy.
  (3) For the analysis basis:
    (A) methodology;
    (B) rationale for inclusion or exclusion of different blocks of business and how pertinent risks were analyzed;
    (C) rationale for degree of rigor in analyzing different blocks of business (including the level of "materiality" that was used in determining how rigorously to analyze different blocks of business);
    (D) criteria for determining asset adequacy (including the precise basis for determining if assets are adequate to cover reserves under "moderately adverse conditions" or other conditions as specified in relevant actuarial standards of practice); and
    (E) whether the impact of federal income taxes was considered and the method of treating reinsurance in the asset adequacy analysis;
  (4) summary of material changes in methods, procedures, or assumptions from prior year's asset adequacy analysis;
  (5) summary of results; and
  (6) conclusions.
(c) Details of the regulatory asset adequacy issues summary.
  (1) The regulatory asset adequacy issues summary must include the following.
    (A) Descriptions of the scenarios tested (including whether those scenarios are stochastic or deterministic) and the sensitivity testing done relative to those scenarios. If negative ending surplus results under certain tests in the aggregate, the actuary should describe those tests and the amount of additional reserve as of the valuation date that, if held, would eliminate the negative aggregate surplus values. Ending surplus values must be determined by either extending the projection period until the in force and associated assets and liabilities at the end of the projection period are immaterial or by adjusting the surplus amount at the end of the projection period by an amount that appropriately estimates the value that can reasonably be expected to arise from the assets and liabilities remaining in force.
    (B) The extent to which the appointed actuary uses assumptions in the asset adequacy analysis that are materially different than the assumptions used in the previous asset adequacy analysis.
    (C) The amount of reserves and the identity of the product lines that had been subjected to asset adequacy analysis in the prior opinion but were not subject to analysis for the current opinion.
    (D) Comments on any interim results that may be of significant concern to the appointed actuary. For example, the comments must describe the impact of the insufficiency of assets to support the payment of benefits and expenses and the establishment of statutory reserves during one or more interim periods.
    (E) The methods used by the actuary to recognize the impact of reinsurance on the company's cash flows, including both assets and liabilities, under each of the scenarios tested.
    (F) Whether the actuary has been satisfied that all options whether explicit or embedded, in any asset or liability (including, but not limited to, those affecting cash flows embedded in fixed income securities) and equity-like features in any investments have been appropriately considered in the asset adequacy analysis.
  (2) The regulatory asset adequacy issues summary must contain the name of the company for which the regulatory asset adequacy issues summary is being supplied and be signed and dated by the appointed actuary rendering the actuarial opinion.
Cont'd...